Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure
NCT ID: NCT01971177
Last Updated: 2014-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
136 participants
INTERVENTIONAL
2013-10-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery
NCT02023437
A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery
NCT01769313
Comparison of Phacoemulsification and Corneal Damage Between FLACS and Standard Phaco With Two Handpieces
NCT05119270
Comparison of Two Fragmentation Modalities in Femtosecond Laser-assisted Cataract Surgery
NCT02898909
Cataract Surgery: Femto LDV Z8 Versus Conventional
NCT02351271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this study patients with different cataract grades \[judged by lens opacity classification system (LOCS) III on nuclear opalescence) will be randomly assigned to either a manual group or a laser group, and aspects on efficacy and safety will be investigated.
* The sponsor and the investigators ensure, that all relevant documents are approved by their institutional review board / institutional ethics committee (IRB/IEC), or if not using their institution's IRB/IEC, approved by the reviewing central IRB/IEC prior to entering any subjects in the study.
* To avoid any potential bias during the process of patient assignment and in order to observe fair and true clinical significance a block randomization method will be employed and applied during the study.
* Subjects are regarded as enrolled to the clinical trial population as soon as they have signed and received the patient informed consent form (ICF) and underwent preoperative examinations.
* The sponsor's clinical group will accompany and monitor this study in respect to patient enrolment, eligibility control, randomization process, postoperative monitoring and data collection in accordance with the applicable regulations and the specifications required by the sponsor.
* All medical information obtained at each study visit will be recorded in the subject's record (source documentation) in real time as it is collected and then transcribed onto the case report form (CRF) by site personnel.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Femtosecond laser cataract surgery
"Laser group": a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure.
Femtosecond laser cataract surgery
The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.
Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.
All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform.
Manual cataract surgery
"Manual": manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation
Manual cataract surgery
"Manual": manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Femtosecond laser cataract surgery
The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.
Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.
All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform.
Manual cataract surgery
"Manual": manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients are willing and able to return for follow-up examinations
* Clear corneal media
* Cataract grade (nuclear) from I to V according to LOCS III
* Patients must be at least 40 years of age
Exclusion Criteria
* Glaucoma and suspected glaucoma
* Patients with pre-existing proliferative diabetic retinopathy (mild and tight controlled diabetes symptoms, without retinopathy and non-proliferative diabetic retinopathy, can be included.)
* Retinal disorders
* Rheumatic diseases
* Occlusion of retinal vessels
* Pellucid marginal degeneration
* Herpes zoster or herpes simplex keratitis
* Heavy vascularization of the ocular tissue
* Epilepsy
* Recurrent corneal erosion
* Severe basement membrane disease
* Patients who suffer from severe wound-healing disorders such as connective tissue disease, autoimmune illnesses, immunodeficiency illnesses,endocrine diseases, lupus, rheumatoid arthritis, collagenosis, or clinically significant atopy
* Patients suffering from AIDS or HIV.
* Chemosis
* Significant loss of stability of the conjunctiva
* Nystagmus
* On a keratometric map of the cornea, the minimum and maximum K-values of the central 3 mm zone must not differ by more than 5 D.
* The maximum K-values must not exceed 60 D. The minimum value must not be smaller than 37 D.
* Patients who are pregnant or nursing.
* Patients who are blind in the fellow eye.
* Known sensitivity to planned concomitant medications.
* Patients with a recurrent or active ocular or uncontrolled eyelid disease.
* Subjects with a poorly dilating pupil.
* Patients with an anterior chamber depth (ACD) \< 1.5 mm or ACD \> 4.8 mm
* Presence of blood or other material in the anterior chamber.
* A history of lens instability (eg. posterior polar cataract, traumatic cataract) or zonular instability
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Technolas Perfect Vision GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pavel Stodulka, Dr. med
Role: PRINCIPAL_INVESTIGATOR
Gemini clinic, Zlin, Czech Republic 76001
Kasu Prasad Reddy, MD
Role: PRINCIPAL_INVESTIGATOR
MaxiVision Laser Centre Private Limited, Hyderabad, India
N Sreelakshmi, MD
Role: PRINCIPAL_INVESTIGATOR
MaxiVision Laser Centre Private Limited, Hyderabad, India
Stephen Slade, MD
Role: STUDY_CHAIR
Slade & Baker Vision Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gemini Eye Clinic
Zlín, , Czechia
MaxiVision Laser Centre Private Limited
Hyderabad, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.